Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Income: 2011-2025

Historic Non Operating Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$449,000.

  • Fennec Pharmaceuticals' Non Operating Income rose 15.76% to -$449,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 32.13%. This contributed to the annual value of -$2.6 million for FY2024, which is 19.40% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Non Operating Income stood at -$449,000, which was down 6.90% from -$420,000 recorded in Q2 2025.
  • Fennec Pharmaceuticals' Non Operating Income's 5-year high stood at $190,000 during Q1 2021, with a 5-year trough of -$1.2 million in Q4 2022.
  • Over the past 3 years, Fennec Pharmaceuticals' median Non Operating Income value was -$686,000 (recorded in 2024), while the average stood at -$649,000.
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 2,011.11% in 2021, then tumbled by 1,483.33% in 2022.
  • Fennec Pharmaceuticals' Non Operating Income (Quarterly) stood at -$12,000 in 2021, then slumped by 1,483.33% to -$1.2 million in 2022, then climbed by 29.30% to -$864,000 in 2023, then rose by 20.60% to -$686,000 in 2024, then rose by 15.76% to -$449,000 in 2025.
  • Its last three reported values are -$449,000 in Q3 2025, -$420,000 for Q2 2025, and -$357,000 during Q1 2025.